The basal cell carcinoma is the most common neoplasia of the periocular region, being responsible for 90% of the eyelid malignancies. There has been a significant rate of increase of the neoplasia during the last few years. Although of slow growth and rarely enticing metastases, its extension and location offer great therapeutic difficulties when it involves the periocular region.The surgical treatment is the one currently used for the periocular region, however, new therapeutic methods have been proposed. The reparative surgical techniques might jeopardize so much the eyelid function (ocular protection) as well as the region aesthetic balance. Recently a new approach involving a clinical treatment using topics immune response modifier has been tried. Imiquimod cream 5% is the main representative of this new class of medications, it has been widely studied in the recent past and it has shown great effectiveness in the treatment of the basal cell carcinoma.he purpose of this current work is accomplishing a systematic analysis of the relevant literature that supports the use of imiquimod cream 5% in the periocular basal cell carcinoma treatment.
Carcinoma, basal cell; Antineoplastic agents; Immunologic factors; Eyelid neoplasms; Review literature
